Barclays PLC Has $1.05 Million Stake in Annexon, Inc. (NASDAQ:ANNX)

Barclays PLC lifted its holdings in shares of Annexon, Inc. (NASDAQ:ANNX) by 212.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 177,765 shares of the company’s stock after acquiring an additional 120,789 shares during the quarter. Barclays PLC’s holdings in Annexon were worth $1,052,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ANNX. FMR LLC lifted its holdings in Annexon by 3.2% during the 3rd quarter. FMR LLC now owns 8,561,949 shares of the company’s stock valued at $50,687,000 after purchasing an additional 262,229 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Annexon by 16.1% in the second quarter. Point72 Asset Management L.P. now owns 5,989,017 shares of the company’s stock valued at $29,346,000 after purchasing an additional 832,617 shares during the period. State Street Corp lifted its stake in shares of Annexon by 116.6% during the 3rd quarter. State Street Corp now owns 3,841,879 shares of the company’s stock worth $22,744,000 after buying an additional 2,068,294 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Annexon by 18.3% during the 3rd quarter. Geode Capital Management LLC now owns 2,143,635 shares of the company’s stock worth $12,693,000 after buying an additional 331,269 shares during the period. Finally, Marshall Wace LLP grew its stake in Annexon by 436.6% in the 2nd quarter. Marshall Wace LLP now owns 1,693,665 shares of the company’s stock valued at $8,299,000 after buying an additional 1,378,053 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ANNX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Annexon in a research note on Tuesday, December 17th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $15.80.

Annexon Stock Down 8.3 %

Shares of NASDAQ:ANNX opened at $4.53 on Wednesday. Annexon, Inc. has a 12-month low of $3.86 and a 12-month high of $8.40. The company’s 50 day moving average price is $5.37 and its two-hundred day moving average price is $5.95. The firm has a market cap of $482.87 million, a PE ratio of -4.31 and a beta of 1.11.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.